Skip to main content
PFE
NYSE Life Sciences

Pfizer's Lyme Vaccine Achieves Over 70% Efficacy in Phase 3, Regulatory Filings Planned

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$26.65
Mkt Cap
$153.359B
52W Low
$20.915
52W High
$27.94
52W Position info
27% above low
Off High info
4.6% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PFE sits 27% above its 52-week low of $20.915.

Summary

Pfizer and Valneva reported positive topline results from their Phase 3 trial for the LB6V Lyme disease vaccine candidate, demonstrating over 70% efficacy in preventing the disease and good tolerability. Despite a statistical criterion not being met in the primary endpoint due to fewer cases than anticipated, the criterion was met in a second pre-specified analysis, and Pfizer expressed confidence in the vaccine's potential. This development is significant for Pfizer, a large-cap pharmaceutical company, as it represents a potential new revenue stream in an area with no currently approved human vaccine. The companies are planning submissions to regulatory authorities, which could lead to the first-to-market solution for Lyme disease. Traders will closely watch the regulatory approval process and subsequent commercialization plans.

At the time of this announcement, PFE was trading at $26.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $153.4B. The 52-week trading range was $20.92 to $27.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 18, 2026, 7:20 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $28.28
Real-time Price: $27.44 info
Change: -$0.840 (-3%) info
Market Cap: $156.176B info
PFE
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.12
Real-time Price: $27.44 info
Change: -$1.68 (-6%) info
Market Cap: $156.176B info
PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $27.44 info
Change: -$1.41 (-5%) info
Market Cap: $156.176B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $27.44 info
Change: -$2.01 (-7%) info
Market Cap: $156.176B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $27.44 info
Change: -$3.22 (-11%) info
Market Cap: $156.176B info